4.7 Article

Anticoagulant therapy for idiopathic pulmonary fibrosis

Journal

CHEST
Volume 128, Issue 3, Pages 1475-1482

Publisher

ELSEVIER
DOI: 10.1378/chest.128.3.1475

Keywords

acute exacerbation; anticoagulant therapy; idiopathic pulmonary fibrrosis; low-molecular-weight heparin; prognosis; survival; warfarin

Ask authors/readers for more resources

Study objective: To evaluate the effect of anticoagulant therapy on the survival of patients with idiopathic pulmonar fibrosis (IPF). Design: Prospective study. Setting: Five hospitals located in the Miyagi prefecture in Japan, including a university hospital, a Red Cross hospital, two public general hospitals, and a municipal hospital. Patients: Fifty-six patients with IPF (mean age, 69.4 years; range, 47 to 89) admitted to the hospitals from April 2001 to April 2004. Interventions: Patients were assigned to receive prednisolone alone or prednisolone plus anticoagulant therapy. The anticoagulants included oral warfarin in an outpatient setting and low-molecular-weight heparin for rehospitalized patients with severely progressive respiratory failure. Measurements and results: There was no difference in baseline characteristics, including age, gender, clinical condition, pulmonary, function, and plasma d-dimer level between the nonanticoagulant group and the anticoagulant group. The overall survival and hospitalization-free periods were assessed. There was a significant difference between survival curves of the nonanticoagulant group and the anticoagulant group, with a 2.9 hazard ratio (p = 0.04, Cox regression model). There was no significant difference in the probability, of a hospitalization-free period between groups. The major cause of clinical deterioration was acute exacerbation during follow-up in the present study. Therefore, the mortality, and plasma d-dimer levels in patients with an acute exacerbation were also assessed. The mortality, associated with acute exacerbations of IPF in the anticoagulant group was significantly reduced compared to that in the nonanticop agulant group (18% vs 71%, respectively; p = 0.008, Fisher Exact Test). Furthermore, the plasma d-dimer levels in patients who died were significantly higher than those in survivors during acute exacerbation of IPF (3.3 +/- 2.3 mu g/mL vs 0.9 +/- 0.7 mu g/mL, p < 0.0001). Histologic analysis performed in three patients who died due to an exacerbation of IPF in the nonanticoagulant group demonstrated the features of usual interstitial pneumonia and acute lung injury. Conclusions: Our data suggested that plasma d-dimer levels are associated with mortality in patients with an acute exacerbation of IPF, and that anticoagulant therapy has a beneficial effect on survival in patients with IPF.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available